Ping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ping Zhang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chan-Jun Zhen
Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
1 shared publication - Jun-Li Liang
Department of Nursing, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
1 shared publication - Shuo-Shuo Wang
Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
1 shared publication - Wen-Wen Bai
Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
1 shared publication - Xian-Shu Gao
Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, China.
1 shared publication - Xueying Qiao
Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publication
Latest Publications
- Open Access
- 27 February 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 54
Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy
The aim of this study was to evaluate the salvage radiotherapy outcome in patients with local recurrent esophageal cancer after radical radiochemotherapy (RCT). A total of 114 patients with local recurrent esophageal squamous cell carcinoma after initial radical RCT were retrospectively analyzed. Fifty-five (55) patients belonged to the salvage radiotherapy group (SR group) and 59 patients to the non-salvage radiotherapy group (NSR group). The median survival time after-recurrence was 4 months in all patients. The 1, 2, 3 year overall survival (OS) rates were 83.6%, 41.8% and 21.8% respectively in the SR group, and 57.6%, 16.9%, and 8.5% in the NSR group. The 6-month and 1-year survival rates after-recurrence were 41.8% and 16.4% respectively in the SR group, and 11.9% and 3.4% respectively in the NSR group. A salvage radiation dose > 50 Gy after initial radical RCT, improved the survival of patients with local recurrent esophageal cancer. Three patients (5.45%) from the SR group showed more than 3-grade radiation pneumonitis. In addition, esophageal fistula/perforation was observed in 11 cases (20.0%) in the SR group and in 8 cases (13.6%) in the NSR group. Salvage treatment after definitive RCT may improve the overall survival and survival after-recurrence of patients with local recurrent esophageal cancer.
- 27 February 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 54
Open AccessSalvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy
The aim of this study was to evaluate the salvage radiotherapy outcome in patients with local recurrent esophageal cancer after radical radiochemotherapy (RCT). A total of 114 patients with local recurrent esophageal squamous cell carcinoma after initial radical RCT were retrospectively analyzed. Fifty-five (55) patients belonged to the salvage radiotherapy group (SR group) and 59 patients to the non-salvage radiotherapy group (NSR group). The median survival time after-recurrence was 4 months in all patients. The 1, 2, 3 year overall survival (OS) rates were 83.6%, 41.8% and 21.8% respectively in the SR group, and 57.6%, 16.9%, and 8.5% in the NSR group. The 6-month and 1-year survival rates after-recurrence were 41.8% and 16.4% respectively in the SR group, and 11.9% and 3.4% respectively in the NSR group. A salvage radiation dose > 50 Gy after initial radical RCT, improved the survival of patients with local recurrent esophageal cancer. Three patients (5.45%) from the SR group showed more than 3-grade radiation pneumonitis. In addition, esophageal fistula/perforation was observed in 11 cases (20.0%) in the SR group and in 8 cases (13.6%) in the NSR group. Salvage treatment after definitive RCT may improve the overall survival and survival after-recurrence of patients with local recurrent esophageal cancer.